XORTX Therapeutics Inc. (XRTX)
- Previous Close
2.6800 - Open
2.6600 - Bid --
- Ask --
- Day's Range
2.5200 - 2.7775 - 52 Week Range
1.9800 - 67.7160 - Volume
21,164 - Avg. Volume
50,474 - Market Cap (intraday)
7.332M - Beta (5Y Monthly) -0.08
- PE Ratio (TTM)
-- - EPS (TTM)
-1.0900 - Earnings Date May 15, 2024 - May 20, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.19
XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, a program to treat acute kidney injury (AKI) associated with respiratory virus infection and associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. It has a collaboration and license agreements with the Icahn School of Medicine; and a license agreement with the University of Florida Research Foundation, Inc. The company is based in Alberta Beach, Canada.
www.xortx.comRecent News: XRTX
Performance Overview: XRTX
Trailing total returns as of 5/10/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: XRTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: XRTX
Valuation Measures
Market Cap
7.33M
Enterprise Value
3.90M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.57
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-34.72%
Return on Equity (ttm)
-37.08%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-2.16M
Diluted EPS (ttm)
-1.0900
Balance Sheet and Cash Flow
Total Cash (mrq)
3.45M
Total Debt/Equity (mrq)
0.25%
Levered Free Cash Flow (ttm)
-4.2M
Research Analysis: XRTX
Company Insights: XRTX
XRTX does not have Company Insights